Beta Bionics prices $150.0 million common stock offering at $17.25 per share
Beta Bionics priced an underwritten public offering of 7,652,175 common shares at $17.25 per share, plus pre-funded warrants for 1,043,484 shares, with gross proceeds expected to be about $150.0 million before underwriting discounts and expenses. The company expects to use the net proceeds for general corporate purposes, including costs of commercializing Mint and manufacturing expansion, and the offering is expected to close on September 17, 2026. The sale of new shares will increase the number of shares outstanding, which affects existing shareholders' ownership.
Key points
- Offering of 7,652,175 common shares at $17.25 per share, plus pre-funded warrants for 1,043,484 shares at $17.2499 per share
- Gross proceeds expected to be about $150.0 million before underwriting discounts and offering expenses
- Underwriters have a 30-day option to buy up to 1,304,348 additional shares at the public offering price
- Expected closing on September 17, 2026; J.P. Morgan, Piper Sandler, Wells Fargo Securities and Leerink Partners are the underwriters
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 16, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.